Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ArriVent BioPharma (AVBP) Long-Term Investments (2024 - 2025)

ArriVent BioPharma has reported Long-Term Investments over the past 2 years, most recently at $5.1 million for Q3 2025.

  • Quarterly results put Long-Term Investments at $5.1 million for Q3 2025, changed N/A from a year ago — trailing twelve months through Sep 2025 was $5.1 million (changed N/A YoY), and the annual figure for FY2024 was $47.7 million, changed.
  • Long-Term Investments reached $5.1 million in Q3 2025 per AVBP's latest filing, down from $18.8 million in the prior quarter.
  • Across five years, Long-Term Investments topped out at $47.7 million in Q4 2024 and bottomed at $5.1 million in Q3 2025.